$210K tit-for-tat Aussie Code fines

 Posted 9 April 2026 AM

The battle for the local obesity market is heating up with a Medicines Australia Code of Conduct complaint by Novo Nordisk resulting in a $130,000 fine for Eli Lilly, which counter-claimed resulting in an $80,000 fine for Novo Nordisk.

After successful intercompany dialogue, an initial, much broader complaint by Novo was whittled down to a dispute over one promotional item - a Leave Behind by Lilly relating to the SURMOUNT-5 head-to-head trial between Mounjaro and Wegovy for weight loss.